Meet The Speakers

  • Thomas Wilckens, Germany I Congress Chair

    Thomas Wilckens, Germany I Congress Chair

    Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine.
  • Richard Barker, UK

    Richard Barker, UK

    Richard is an internationally respected leader in healthcare and life sciences. 

    He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the worldwide development and adoption of precision medicine.
  • Jan Baumbach, Germany

    Jan Baumbach, Germany

    Jan Baumbach studied Applied Computer Science in the Natural Sciences at Bielefeld University in Germany. His research career started at Rothamsted Research in Harpenden (UK) where he worked on computational methods for the integration of molecular biology data. 
  • Catherine Brownstein, USA

    Catherine Brownstein, USA

    Dr. Brownstein is an Instructor in Pediatrics at Harvard Medical School and a Research Associate in the Division of Genetics and Genomics at Boston Children's Hospital.
  • Jonathan Darrow, USA

    Jonathan Darrow, USA

    Dr. Darrow is a faculty member at Harvard Medical School and a core faculty member of the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham & Women's Hospital, where he focuses on the intersection of innovation policy and pharmaceuticals.
  • Isabelle Duroux-Richard, France

    Isabelle Duroux-Richard, France

    Isabelle Duroux-Richard has a long-lasting experience in studying miRNA-controlled regulatory loops in the pathophysiology of rheumatisms, which includes expertise in antisens approach, RNA interference, microRNAs, and transcriptomic and bioinformatic analyses. 
  • Philipp Geyer, Germany

    Philipp Geyer, Germany

    Philipp Geyer studied Molecular Biotechnology at the Technical University of Munich (TUM) and did his PhD thesis in Matthias Mann´s group at the Max Planck Institute of Biochemistry in Martinsried. The overall aim of his PhD was to pave the way for biomarker discovery and clinical applications of proteomics by precision characterization of the human blood plasma proteome. 
  • Roberta Gualtierotti, Italy

    Roberta Gualtierotti, Italy

    Roberta Gualtierotti is a specialist in Rheumatology, with experience in autoimmune and inflammatory rheumatic diseases. After presenting a thesis on fibroblast-like synoviocytes in rheumatoid arthritis, she was awarded a PhD in Experimental Pathology and Neuropathology by the University of Milan, where she is currently a post-doctoral fellow at the Department of Medical Biotechnology and Translational Medicine.
  • Amnon Hezkiya, Israel

    Amnon Hezkiya, Israel

    Amnon Hezkiya, innovation policy and strategy consultant with vast entrepreneurial and management experience. He is the secretary of the committee for artificial intelligence, machine learning and data Science in the healthcare arena at the Israeli National Initiative for Intelligent Systems.
  • Thomas Hügle, Switzerland

    Thomas Hügle, Switzerland

    Prof. Thomas Hügle has obtained his medical degree at the University of Freiburg in Germany 2001. He performed his clinical training in Internal Medicine and Rheumatology at the Ospedale Civico in Lugano (Switzerland) and the University Hospital in Basel.
  • Mark Jamilkowski, USA

    Mark Jamilkowski, USA

    Mark Jamilkowski is an actuary and experienced healthcare consultant with nearly 30 years of healthcare industry experience.  Mark has delivered healthcare management advisory services to provider-based organizations, health insurance companies, and government entities.  Prior to this role, he was a Managing Director at KPMG.  Mark, also a proud father, enjoys chess and music.
  • Tim Kacprowski, Germany

    Tim Kacprowski, Germany

    Tim Kacprowski heads the research group Computational Systems Medicine at the Chair of Experimental Bioinformatics at TUM. His group works on network biology, multi omics integration and machine learning in the context of biomedicine.  Previously, he was a PostDoc at the Syddansk Universitet in Odense, Denmark. 
  • Gabi Kastenmüller, Germany

    Gabi Kastenmüller, Germany

    Gabi Kastenmüller is heading a research group on systems metabolomics within the Institute of Bioinformatics and Systems Biology (IBIS) at the Helmholtz Zentrum München (HMGU), Germany, and currently also serves as acting director of the institute. 
  • Michael Liebman, USA

    Michael Liebman, USA

    Michael N. Liebman, Ph.D (theoretical chemistry and protein crystallography) is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007. 
  • Yves Lussier, USA

    Yves Lussier, USA

    Dr. Lussier is the Associate VP for Information Science at the University of Arizona, Founding Director of the Center for Biomedical Informatics and Biostatistics. His research group conducts hypothesis-driven computational modeling predictions in precision medicine that are then validated in vitro, in vivo and in clinical trials. 
  • Herna Muñoz-Galeano, Germany

    Herna Muñoz-Galeano, Germany

    Herna Muñoz-Galeano is the managing director and owner of HMG with more than 25 years of experience in the fields of specification, development, integration and management of complex engineering systems. Since 1998, Herna has been an independent entrepreneur with a special interest in transforming science into innovative products and systems. 
  • Harsukh Parmar, USA

    Harsukh Parmar, USA

    Harsukh completed his medical training at Aberdeen University and post-graduate clinical, academic and research training in internal medicine, immunology & oncology at Westminster & Charing Cross Hospitals, London (Imperial Medical School). He joined Pfizer Central Research in 1994 in the Dept of Experimental Medicine as Clinical Project Manager/Associate Director. 
  • Nikolaus Rieber, Germany

    Nikolaus Rieber, Germany

    Nikolaus Rieber studied medicine at the University of Munich. He achieved his doctor’s degree for the work on the Notch signaling pathway in myelopoiesis at the Helmholtz center Munich. He completed his specialisation in pediatrics, infectious diseases and pediatric rheumatology at the University children’s hospitals of Munich and Tübingen.
  • Gabriela Riemekasten, Germany

    Gabriela Riemekasten, Germany

    Prof. Dr. Gabriela Riemekasten is the Director of Clinic for Rheumatology and Clinical Immunology at the University OF Schleswig Holstein, Germany. Gabriele has a special interest in connective tissue diseases (systemic sclerosis, systemic lupus erythematosus, etc.).
  • Markus Rinecker, Germany

    Markus Rinecker, Germany

    Before taking the entrepreneur route, Markus Rinecker was member of the executive board of Definiens AG, an AstraZeneca company, between 2009 and 2019. As CFO he has secured capital for growth and guided Definiens’ integration with AstraZeneca after its acquisition in 2014.
  • Marie Skougaard, Denmark

    Marie Skougaard, Denmark

    Marie Skougaard is a medical doctor that after graduating from University of Copenhagen have gained insight into the broad domains of inflammatory diseases from various research and clinical internships.
  • Alain van Gool, The Netherlands

    Alain van Gool, The Netherlands

    Alain van Gool is professor Personalized Healthcare and heads the Translational Metabolic Laboratory at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. 
  • Lutz Weber, Germany

    Lutz Weber, Germany

    Dr. Lutz Weber, a trained medicinal chemist and pharmacist, has started OntoChem IT Solutions in 2015. The company is developing new tools to navigate today's complex scientific information such as SciWalker Open Access. High quality, comprehensive extracted data is aiming to create predictive tools for tomorrows Medicines.